Abstract Details
8/22/2022 | 2:15 PM - 2:40 PM | Governor General III
What the COVID Pandemic Taught Us About Congenital CMV!
Objective: To describe the demographics and changing prevalence of cCMV infection in a universal screening study in Minnesota before and during the COVID-19 pandemic. Design/Methods: In six newborn nurseries in the Twin Cities, Minnesota, consented newborns were screened for cCMV using saliva collected 1-2 days after birth and dried blood spot (DBS) obtained for routine newborn screening. Screen-positive infants had a confirmatory urine sample tested by PCR within 3 weeks of birth. Results: During February 2016–December 2021, 19,919 newborns screened, and 76 (3.8 per 1,000) were identified with cCMV. A total of 15,699 were screened during the pre-pandemic period (2/2016–3/2020, 70 cCMV cases identified; 4.5 per 1,000), and 4,220 during the pandemic period (8/2020–12/2021, 6 cCMV cases identified; 1.4 per 1,000; p<0.01 compared to pre-pandemic). Conclusions: The prevalence of cCMV decreased significantly during the COVID-19 pandemic. Understanding the impact on cCMV prevalence conferred by mitigation measures related to childcare during the pandemic (e.g., decreased daycare utilization, increased hand hygiene and disinfection) might inform future prevention strategies focused on hygiene promotion and behavior change.
- Know how the COVID pandemic impacted the prevalence of cCMV infection during a universal screening study in Minnesota.
- Recognize that pandemic mitigation measures likely decreased transmission of CMV to pregnant women.
- Discuss how this knowledge applies to cCMV prevention strategies.
Presentation:
This presentation has not yet been uploaded.
Handouts:
No handouts have been uploaded.
Mark R. Schleiss (POC-Point of Contact,Primary Presenter), schleiss@umn.edu ;
Dr. Schleiss is a Professor of Pediatrics and holds the American Legion and Auxiliary Endowed Research Chair at the University of Minnesota Medical School. His laboratory is supported by the NIH. He conducts research in small animal models testing vaccine strategies against congenital CMV infection. His laboratory is also engaged in the study of the epidemiology, pathogenesis and management of congenital and neonatal CMV infections.
|
ASHA DISCLOSURE: Financial - Receives Consulting fee for Consulting from Moderna vaccines.. Nonfinancial - No relevant nonfinancial relationship exists. |
|
AAA DISCLOSURE: Financial - Receives support from Dr. Schleiss - consultant. for Moderna vaccines.. |